M
Mari Iida
Researcher at University of Wisconsin-Madison
Publications - 69
Citations - 3344
Mari Iida is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Cetuximab & Epidermal growth factor receptor. The author has an hindex of 27, co-authored 60 publications receiving 2923 citations. Previous affiliations of Mari Iida include National Institutes of Health.
Papers
More filters
Journal ArticleDOI
The role of Src in solid tumors.
TL;DR: The role of SFKs in solid tumors and the recent therapeutic advances aimed at targeting this family of tyrosine kinases in cancer are discussed.
Journal ArticleDOI
Nuclear EGFR contributes to acquired resistance to cetuximab.
TL;DR: It is demonstrated that cetuximab-resistant cells overexpress HER family ligands including epidermal growth factor (EGF), amphiregulin, heparin-binding EGF and β-cellulin, which suggest that nuclear expression of EGFR may be an important molecular determinant of resistance to cetUXimab therapy.
Journal Article
The nuclear epidermal growth factor receptor signaling network and its role in cancer
TL;DR: The current knowledge of the nuclear EGFR signaling network is summarized, including how it is trafficked to the nucleus, the functions it serves inThe nucleus, and how these functions impact cancer progression, survival, and response to chemotherapeutics.
Journal ArticleDOI
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
TL;DR: The biology of the EGFR, the role of EGFR in human cancer, the development of antibody-based anti-EGFR therapies and a summary of their clinical successes are focused on.
Journal ArticleDOI
Nuclear EGFR as a molecular target in cancer
TL;DR: The current knowledge of how nuclear EGFR enhances resistance to cancer therapeutics is discussed, in addition to highlighting ways to targetnuclear EGFR as an anti-cancer strategy in the future.